Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension

N. Tamura, Hiroshi Itoh, A. Takahashi, K. Iwai, T. Yoshimasa, I. Masuda, H. Arai, S. Suga, Y. Ogawa, I. Kishimoto, Y. Komatsu, O. Nakagawa, N. Hama, K. Takaya, Y. Miyamoto, T. Igaki, M. Harada, J. Yamashita, K. Nakao

Research output: Contribution to journalArticle

Abstract

We examined the alternation of the plasma atrial and brain natriuretic peptide (ANP and BNP) concentrations during clinical course of a 57-year-old male with malignant hypertension. The patient exhibited marked elevation of diastolic blood pressure up to 152 mmHg with progressive organ damages snch as concentric cardiac hypertrophy, hypertensive retinopathy, and renal insufficiency. In the present case, extreme hypertension and markedly activated renin-angiotensin system (the plasma renin activity, 35.3 ng/ml/h; the plasma aldosterone concentration, 321.4 pg/ml) caused cardiac overload and hypertrophy (the left ventricular mass index, 161 g/m2) which was considered to lead to marked increase of the plasma BNP concentration (1195.5 pg/ml), much higher than the concomitantly elevated plasma ANP concentration (197.1 pg/ml). During the clinical course, the blood pressure decreased trom 268/152 mmHg to 148/82 mmHg, and the left ventricular mass index decreased from 161 g/m2 to 136 g/m2, in response to the anti-hypertensive therapy with Ca-entry blockers and angiotensin converting enzyme inhibitors. Following the decrease of blood pressure and regression of cardiac hypertrophy, the elevated plasma BNP concentration significantly decreased to 47.7 pg/ml, lower than the concomitantly decreased plasma ANP concentration (68.8 pg/ml). The present report indicates the usefulness of the plasma BNP concentration as a marker to determine the severity of cardiac overload and hypertrophy during the clinical course of hypertensive patients.

Original languageEnglish
Pages (from-to)197-204
Number of pages8
JournalTherapeutic Research
Volume15
Issue number7
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Malignant Hypertension
Brain Natriuretic Peptide
Atrial Natriuretic Factor
Cardiomegaly
Blood Pressure
Hypertensive Retinopathy
Renin-Angiotensin System
Aldosterone
Angiotensin-Converting Enzyme Inhibitors
Renin
Antihypertensive Agents
Renal Insufficiency
Hypertension

Keywords

  • angiotensin II
  • atrial natriuretic peptide
  • brain natriuretic peptide
  • cardiac hypertrophy
  • malignant hypertension
  • renin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tamura, N., Itoh, H., Takahashi, A., Iwai, K., Yoshimasa, T., Masuda, I., ... Nakao, K. (1994). Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension. Therapeutic Research, 15(7), 197-204.

Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension. / Tamura, N.; Itoh, Hiroshi; Takahashi, A.; Iwai, K.; Yoshimasa, T.; Masuda, I.; Arai, H.; Suga, S.; Ogawa, Y.; Kishimoto, I.; Komatsu, Y.; Nakagawa, O.; Hama, N.; Takaya, K.; Miyamoto, Y.; Igaki, T.; Harada, M.; Yamashita, J.; Nakao, K.

In: Therapeutic Research, Vol. 15, No. 7, 1994, p. 197-204.

Research output: Contribution to journalArticle

Tamura, N, Itoh, H, Takahashi, A, Iwai, K, Yoshimasa, T, Masuda, I, Arai, H, Suga, S, Ogawa, Y, Kishimoto, I, Komatsu, Y, Nakagawa, O, Hama, N, Takaya, K, Miyamoto, Y, Igaki, T, Harada, M, Yamashita, J & Nakao, K 1994, 'Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension', Therapeutic Research, vol. 15, no. 7, pp. 197-204.
Tamura N, Itoh H, Takahashi A, Iwai K, Yoshimasa T, Masuda I et al. Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension. Therapeutic Research. 1994;15(7):197-204.
Tamura, N. ; Itoh, Hiroshi ; Takahashi, A. ; Iwai, K. ; Yoshimasa, T. ; Masuda, I. ; Arai, H. ; Suga, S. ; Ogawa, Y. ; Kishimoto, I. ; Komatsu, Y. ; Nakagawa, O. ; Hama, N. ; Takaya, K. ; Miyamoto, Y. ; Igaki, T. ; Harada, M. ; Yamashita, J. ; Nakao, K. / Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension. In: Therapeutic Research. 1994 ; Vol. 15, No. 7. pp. 197-204.
@article{24c19b00917b41beb5c4082aaed2eeea,
title = "Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension",
abstract = "We examined the alternation of the plasma atrial and brain natriuretic peptide (ANP and BNP) concentrations during clinical course of a 57-year-old male with malignant hypertension. The patient exhibited marked elevation of diastolic blood pressure up to 152 mmHg with progressive organ damages snch as concentric cardiac hypertrophy, hypertensive retinopathy, and renal insufficiency. In the present case, extreme hypertension and markedly activated renin-angiotensin system (the plasma renin activity, 35.3 ng/ml/h; the plasma aldosterone concentration, 321.4 pg/ml) caused cardiac overload and hypertrophy (the left ventricular mass index, 161 g/m2) which was considered to lead to marked increase of the plasma BNP concentration (1195.5 pg/ml), much higher than the concomitantly elevated plasma ANP concentration (197.1 pg/ml). During the clinical course, the blood pressure decreased trom 268/152 mmHg to 148/82 mmHg, and the left ventricular mass index decreased from 161 g/m2 to 136 g/m2, in response to the anti-hypertensive therapy with Ca-entry blockers and angiotensin converting enzyme inhibitors. Following the decrease of blood pressure and regression of cardiac hypertrophy, the elevated plasma BNP concentration significantly decreased to 47.7 pg/ml, lower than the concomitantly decreased plasma ANP concentration (68.8 pg/ml). The present report indicates the usefulness of the plasma BNP concentration as a marker to determine the severity of cardiac overload and hypertrophy during the clinical course of hypertensive patients.",
keywords = "angiotensin II, atrial natriuretic peptide, brain natriuretic peptide, cardiac hypertrophy, malignant hypertension, renin",
author = "N. Tamura and Hiroshi Itoh and A. Takahashi and K. Iwai and T. Yoshimasa and I. Masuda and H. Arai and S. Suga and Y. Ogawa and I. Kishimoto and Y. Komatsu and O. Nakagawa and N. Hama and K. Takaya and Y. Miyamoto and T. Igaki and M. Harada and J. Yamashita and K. Nakao",
year = "1994",
language = "English",
volume = "15",
pages = "197--204",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "7",

}

TY - JOUR

T1 - Plasma atrial and brain natriuretic peptide concentrations in a case of malignant hypertension

AU - Tamura, N.

AU - Itoh, Hiroshi

AU - Takahashi, A.

AU - Iwai, K.

AU - Yoshimasa, T.

AU - Masuda, I.

AU - Arai, H.

AU - Suga, S.

AU - Ogawa, Y.

AU - Kishimoto, I.

AU - Komatsu, Y.

AU - Nakagawa, O.

AU - Hama, N.

AU - Takaya, K.

AU - Miyamoto, Y.

AU - Igaki, T.

AU - Harada, M.

AU - Yamashita, J.

AU - Nakao, K.

PY - 1994

Y1 - 1994

N2 - We examined the alternation of the plasma atrial and brain natriuretic peptide (ANP and BNP) concentrations during clinical course of a 57-year-old male with malignant hypertension. The patient exhibited marked elevation of diastolic blood pressure up to 152 mmHg with progressive organ damages snch as concentric cardiac hypertrophy, hypertensive retinopathy, and renal insufficiency. In the present case, extreme hypertension and markedly activated renin-angiotensin system (the plasma renin activity, 35.3 ng/ml/h; the plasma aldosterone concentration, 321.4 pg/ml) caused cardiac overload and hypertrophy (the left ventricular mass index, 161 g/m2) which was considered to lead to marked increase of the plasma BNP concentration (1195.5 pg/ml), much higher than the concomitantly elevated plasma ANP concentration (197.1 pg/ml). During the clinical course, the blood pressure decreased trom 268/152 mmHg to 148/82 mmHg, and the left ventricular mass index decreased from 161 g/m2 to 136 g/m2, in response to the anti-hypertensive therapy with Ca-entry blockers and angiotensin converting enzyme inhibitors. Following the decrease of blood pressure and regression of cardiac hypertrophy, the elevated plasma BNP concentration significantly decreased to 47.7 pg/ml, lower than the concomitantly decreased plasma ANP concentration (68.8 pg/ml). The present report indicates the usefulness of the plasma BNP concentration as a marker to determine the severity of cardiac overload and hypertrophy during the clinical course of hypertensive patients.

AB - We examined the alternation of the plasma atrial and brain natriuretic peptide (ANP and BNP) concentrations during clinical course of a 57-year-old male with malignant hypertension. The patient exhibited marked elevation of diastolic blood pressure up to 152 mmHg with progressive organ damages snch as concentric cardiac hypertrophy, hypertensive retinopathy, and renal insufficiency. In the present case, extreme hypertension and markedly activated renin-angiotensin system (the plasma renin activity, 35.3 ng/ml/h; the plasma aldosterone concentration, 321.4 pg/ml) caused cardiac overload and hypertrophy (the left ventricular mass index, 161 g/m2) which was considered to lead to marked increase of the plasma BNP concentration (1195.5 pg/ml), much higher than the concomitantly elevated plasma ANP concentration (197.1 pg/ml). During the clinical course, the blood pressure decreased trom 268/152 mmHg to 148/82 mmHg, and the left ventricular mass index decreased from 161 g/m2 to 136 g/m2, in response to the anti-hypertensive therapy with Ca-entry blockers and angiotensin converting enzyme inhibitors. Following the decrease of blood pressure and regression of cardiac hypertrophy, the elevated plasma BNP concentration significantly decreased to 47.7 pg/ml, lower than the concomitantly decreased plasma ANP concentration (68.8 pg/ml). The present report indicates the usefulness of the plasma BNP concentration as a marker to determine the severity of cardiac overload and hypertrophy during the clinical course of hypertensive patients.

KW - angiotensin II

KW - atrial natriuretic peptide

KW - brain natriuretic peptide

KW - cardiac hypertrophy

KW - malignant hypertension

KW - renin

UR - http://www.scopus.com/inward/record.url?scp=0028142947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028142947&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028142947

VL - 15

SP - 197

EP - 204

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 7

ER -